Title | Creator | Date | ||
---|---|---|---|---|
1 | Sharp Edge Eye Syndrome: A Case Report and Survey of Self-Identified Individuals | Merrick S. Reynolds; Bradley J. Katz; Kathleen B. Digre, Ben J. Brintz; Lenora M. Olson; Judith E. A. Warner | 2022-12 | |
2 | The Impact of Leber Hereditary Optic Neuropathy on the Quality of Life of Patients and Their Relatives: A Qualitative Study | Benson S. Chen, Erik Holzinger, Magali Taiel, Patrick Yu-Wai-Man | 2022-09 | |
3 | Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach | Raymond S. Douglas, Andrea L. Kossler, Jody Abrams, Cesar A. Briceño, David Gay, Andrew Harrison, Michael Lee, John Nguyen, Shannon S. Joseph, Dianne Schlachter, Jeremy Tan, Judah Lynch, Louisa Oliver, Richard Perry, Shoaib Ugradar | 2022-09 | |
4 | Impact of Greater Occipital Nerve Block on Photophobia Levels in Migraine Patients | Javier A Membrilla, Íñigo de Lorenzo, Lucía Sánchez-Casado, María Sastre, Javier Díaz de Terán | 2022-09 | |
5 | Rehabilitation of Visual Loss: Where We Are and Where We Need to Be | Behzad Mansouri, MD, PhD, FRCPC, Marinya Roznik, BSc, Joseph F. Rizzo III, MD,Sashank Prasad, MD | 2018-06 | |
6 | More Than Meets the Eye: The Eye and Migraine -- What You Need to Know | Kathleen B. Digre, MD | 2018-06 | |
7 | Safety and Tolerability of Acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial | Martin W. ten Hove, MD, Deborah I. Friedman, MD, Anil D. Patel, MD, Isabella Irrcher, PhD, Michael Wall, MD, Michael P. McDermott, PhD, for the NORDIC Idiopathic Intracranial Hypertension Study Group | 2016-03 | |
8 | Factors Affecting Visual Field Outcomes in the Idiopathic Intracranial Hypertension Treatment Trial | Kimberly E. Cello, BS, John L. Keltner, MD, Chris A. Johnson, PhD, Michael Wall, MD for the NORDIC Idiopathic Intracranial Hypertension Study Group | 2016-03 |